Clinical Drug Investigation

, Volume 33, Issue 8, pp 563–570

Effects of Mitiglinide, a Short-Acting Insulin Secretagogue, on Daily Glycemic Variability and Oxidative Stress Markers in Japanese Patients with Type 2 Diabetes Mellitus

  • Noriko Kodani
  • Yoshifumi Saisho
  • Kumiko Tanaka
  • Toshihide Kawai
  • Hiroshi Itoh
Original Research Article

Abstract

Background and Objective

The objective of this study was to clarify the effects of mitiglinide on daily glycemic variability and oxidative stress markers in outpatients with type 2 diabetes mellitus that is insufficiently controlled by diet and/or non-insulin secretagogues.

Methods

We enrolled 24 patients with type 2 diabetes whose glycemic control had been suboptimal [i.e. glycosylated hemoglobin (HbA1c) ≥6.9 %]. The patients were treated with mitiglinide 10 mg three times daily for 16 weeks. If their glycemic control was not improved at week 8, the dose of mitiglinide was increased to 20 mg three times daily. Daily glycemic variability was assessed by 7-point self-monitoring of blood glucose for 2 days, and standard deviation (SD), M value, and mean of daily differences (MODD) were calculated. Oxidative stress was assessed by oxidized low-density lipoprotein, pentosidine, urinary 8-iso-prostaglandin F2alpha, and urinary 8-hydroxydeoxy guanosine.

Results

After 16 weeks of mitiglinide treatment, the HbA1c level was significantly decreased (mean ± SD, 7.4 ± 0.7 to 6.8 ± 0.5 %, P < 0.0001). Postprandial glucose excursion and glycemic variability were also significantly improved after mitiglinide treatment (all P < 0.05). The reductions in SD, M value, and MODD were 17, 50, and 48 %, respectively. There was a significant positive correlation between the change in HbA1c and change in SD during the study (r = 0.454, P = 0.03). There were no significant changes in oxidative stress markers.

Conclusions

The present study supports the notion that mitiglinide improves postprandial glucose excursion and HbA1c level in patients with type 2 diabetes. In addition, we demonstrated that mitiglinide also effectively improves daily glycemic variability. The effect of mitiglinide on oxidative stress needs further investigation.

References

  1. 1.
    Kawamori R. Diabetes trends in Japan. Diabetes Metab Res Rev. 2002;18(Suppl 3):S9–13.PubMedCrossRefGoogle Scholar
  2. 2.
    Saito I. Epidemiological evidence of type 2 diabetes mellitus, metabolic syndrome, and cardiovascular disease in Japan. Circ J. 2012;76:1066–73.PubMedCrossRefGoogle Scholar
  3. 3.
    DECODE Study Group, the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med. 2001;161:397–405.CrossRefGoogle Scholar
  4. 4.
    DECODA Study Group, International Diabetes Epidemiology Group. Cardiovascular risk profile assessment in glucose-intolerant Asian individuals—an evaluation of the World Health Organization two-step strategy: the DECODA study (Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Asia). Diabet Med. 2002;19:549–57.CrossRefGoogle Scholar
  5. 5.
    Cavalot F, Petrelli A, Traversa M, et al. Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. J Clin Endocrinol Metab. 2006;91:813–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Tominaga M, Eguchi H, Manaka H, et al. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care. 1999;22:920–4.PubMedCrossRefGoogle Scholar
  7. 7.
    Nakagami T, The DECODA Study Group. Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin. Diabetologia. 2004;47:385–94.PubMedCrossRefGoogle Scholar
  8. 8.
    Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010;107:1058–70.PubMedCrossRefGoogle Scholar
  9. 9.
    Esposito K, Nappo F, Marfella R, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation. 2002;106:2067–72.PubMedCrossRefGoogle Scholar
  10. 10.
    Ceriello A. New insights on oxidative stress and diabetic complications may lead to a “causal” antioxidant therapy. Diabetes Care. 2003;26:1589–96.PubMedCrossRefGoogle Scholar
  11. 11.
    Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006;295:1681–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Kaiser N, Nesher R, Oprescu A, et al. Characterization of the action of S 21403 (mitiglinide) on insulin secretion and biosynthesis in normal and diabetic beta-cells. Br J Pharmacol. 2005;146:872–81.PubMedCrossRefGoogle Scholar
  13. 13.
    Konya H, Miuchi M, Konishi K, et al. Pleiotropic effects of mitiglinide in type 2 diabetes mellitus. J Int Med Res. 2009;37:1904–12.PubMedCrossRefGoogle Scholar
  14. 14.
    Pratley RE, Foley JE, Dunning BE. Rapid acting insulinotropic agents: restoration of early insulin secretion as a physiologic approach to improve glucose control. Curr Pharm Des. 2001;7:1375–97.PubMedCrossRefGoogle Scholar
  15. 15.
    Ohnota H, Koizumi T, Tsutsumi N, et al. Novel rapid- and short-acting hypoglycemic agent, a calcium(2s)-2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl) propionate (KAD-1229) that acts on the sulfonylurea receptor: comparison of effects between KAD-1229 and gliclazide. J Pharmacol Exp Ther. 1994;269:489–95.PubMedGoogle Scholar
  16. 16.
    Assaloni R, Da Ros R, Quagliaro L, et al. Effects of S21403 (mitiglinide) on postprandial generation of oxidative stress and inflammation in type 2 diabetic patients. Diabetologia. 2005;48:1919–24.PubMedCrossRefGoogle Scholar
  17. 17.
    Kashiwagi A, Kasuga M, Araki E, et al. International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National Glycohemoglobin Standardization Program values. J Diabetes Investig. 2012;2012(3):39–40.CrossRefGoogle Scholar
  18. 18.
    Yoshiuchi K, Matsuhisa M, Katakami N, et al. Glycated albumin is a better indicator for glucose excursion than glycated hemoglobin in type 1 and type 2 diabetes. Endocr J. 2008;55:503–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Saisho Y, Tanaka K, Abe T, et al. Glycated albumin to glycated hemoglobin ratio reflects postprandial glucose excursion and relates to beta cell function in both type 1 and type 2 diabetes. Diabetol Int. 2011;2:146–53.CrossRefGoogle Scholar
  20. 20.
    Nakano M, Kawanishi Y, Kamohara S, et al. Oxidative DNA damage (8-hydroxydeoxyguanosine) and body iron status: a study on 2507 healthy people. Free Radic Biol Med. 2003;35:826–32.PubMedCrossRefGoogle Scholar
  21. 21.
    Schlichtkrull J, Munck O, Jersild M. The M-valve, an index of blood sugar control in diabetics. Acta Med Scand. 1965;177:95–102.PubMedCrossRefGoogle Scholar
  22. 22.
    Molnar GD, Taylor WF, Ho MM. Day-to-day variation of continuously monitored glycaemia: a further measure of diabetic instability. Diabetologia. 1972;8:342–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Saisho Y, Shimada A, Kawai T, et al. Effectiveness of switching from mitiglinide 30 mg or nateglinide 270 mg daily to mitiglinide 60 mg daily on glycemic control and body weight in type 2 diabetic patients. J New Rem Clin. 2010;59:950–9.Google Scholar
  24. 24.
    Gao X. Multicentre, double-blind, randomized study of mitiglinide compared with nateglinide in type 2 diabetes mellitus patients in China. J Int Med Res. 2009;37:812–21.PubMedCrossRefGoogle Scholar
  25. 25.
    Kaku K, Tanaka S, Origasa H, et al. Effect of mitiglinide on glycemic control over 52 weeks in Japanese type 2 diabetic patients insufficiently controlled with pioglitazone monotherapy. Endocr J. 2009;56:739–46.PubMedCrossRefGoogle Scholar
  26. 26.
    Chiasson JL. Acarbose for the prevention of diabetes, hypertension, and cardiovascular disease in subjects with impaired glucose tolerance: the Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) Trial. Endocr Pract. 2006;12(Suppl 1):25–30.PubMedCrossRefGoogle Scholar
  27. 27.
    Hanefeld M, Cagatay M, Petrowitsch T, et al. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J. 2004;25:10–6.PubMedCrossRefGoogle Scholar
  28. 28.
    Esposito K, Ciotola M, Carleo D, et al. Post-meal glucose peaks at home associate with carotid intima-media thickness in type 2 diabetes. J Clin Endocrinol Metab. 2008;93:1345–50.PubMedCrossRefGoogle Scholar
  29. 29.
    Ceriello A, Esposito K, Piconi L, et al. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes. 2008;57:1349–54.PubMedCrossRefGoogle Scholar
  30. 30.
    Kondo A, Manabe M, Saito K, et al. Insulin treatment prevents LDL from accelerated oxidation in patients with diabetes. J Atheroscler Thromb. 2002;9:280–7.PubMedCrossRefGoogle Scholar
  31. 31.
    Su Y, Xu Y, Sun YM, et al. Comparison of the effects of simvastatin versus atorvastatin on oxidative stress in patients with type 2 diabetes mellitus. J Cardiovasc Pharmacol. 2010;55:21–5.PubMedCrossRefGoogle Scholar
  32. 32.
    Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–207.PubMedCrossRefGoogle Scholar
  33. 33.
    Monnier L, Colette C, Mas E, et al. Regulation of oxidative stress by glycaemic control: evidence for an independent inhibitory effect of insulin therapy. Diabetologia. 2010;53:562–71.PubMedCrossRefGoogle Scholar
  34. 34.
    Seaquist ER, Kahn SE, Clark PM, et al. Hyperproinsulinemia is associated with increased beta cell demand after hemipancreatectomy in humans. J Clin Investig. 1996;97:455–60.PubMedCrossRefGoogle Scholar
  35. 35.
    Inoguchi T, Umeda F, Kakimoto M, et al. Chronic sulfonylurea treatment and hyperglycemia aggravate disproportionately elevated plasma proinsulin levels in patients with type 2 diabetes. Endocr J. 2000;47:763–70.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  • Noriko Kodani
    • 1
  • Yoshifumi Saisho
    • 1
  • Kumiko Tanaka
    • 1
  • Toshihide Kawai
    • 1
  • Hiroshi Itoh
    • 1
  1. 1.Department of Internal MedicineKeio University School of MedicineTokyoJapan

Personalised recommendations